About Humacyte, Inc.
https://humacyte.comHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
CEO
Laura E. Niklason
Compensation Summary
(Year 2022)
Salary $500,000
Bonus $212,500
All Other Compensation $5,348
Total Compensation $1,749,088
Industry Biotechnology
Sector Healthcare
Went public December 1, 2020
Method of going public SPAC
Full time employees 218
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $180.43 M
52w High $0.23
52w Low $0.12
P/E -0.04
Volume 19.09K
Outstanding Shares 1.20B
About Humacyte, Inc.
https://humacyte.comHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $753K ▲ | $24.88M ▼ | $-17.51M ▲ | -2.33K% ▲ | $-0.11 ▲ | $-13.03M ▲ |
| Q2-2025 | $301K ▼ | $27.95M ▲ | $-37.66M ▼ | -12.51K% ▼ | $-0.24 ▼ | $-33.25M ▼ |
| Q1-2025 | $517K ▼ | $21.72M ▼ | $39.14M ▲ | 7.57K% ▲ | $0.28 ▲ | $43.97M ▲ |
| Q4-2024 | $7.23M ▲ | $31.7M ▲ | $-20.94M ▲ | -289.71% ▼ | $-0.16 ▲ | $-16.62M ▲ |
| Q3-2024 | $0 | $28.42M | $-39.2M | 0% | $-0.33 | $-34.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $19.49M ▼ | $91.51M ▼ | $96.26M ▼ | $-4.75M ▼ |
| Q2-2025 | $38.03M ▼ | $138.79M ▼ | $134.74M ▲ | $4.05M ▼ |
| Q1-2025 | $62.85M ▲ | $162.55M ▲ | $126.51M ▼ | $36.04M ▲ |
| Q4-2024 | $44.94M ▲ | $137.87M ▲ | $190.54M ▲ | $-52.67M ▲ |
| Q3-2024 | $20.57M | $114.76M | $178.49M | $-63.72M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.51M ▲ | $-23.9M ▲ | $-49K ▲ | $-44.59M ▼ | $-68.54M ▼ | $-23.95M ▲ |
| Q2-2025 | $-37.66M ▼ | $-26.41M ▲ | $-568K ▼ | $2.17M ▼ | $-24.96M ▼ | $-26.98M ▲ |
| Q1-2025 | $39.14M ▲ | $-28.6M ▼ | $-228K ▼ | $46.74M ▼ | $17.91M ▼ | $-28.83M ▼ |
| Q4-2024 | $-20.94M ▲ | $-26.58M ▼ | $-63K ▲ | $51.01M ▲ | $24.37M ▲ | $-26.64M ▼ |
| Q3-2024 | $-39.2M | $-22.91M | $-934K | $849K | $-22.99M | $-23.84M |
CEO
Laura E. Niklason
Compensation Summary
(Year 2022)
Salary $500,000
Bonus $212,500
All Other Compensation $5,348
Total Compensation $1,749,088
Industry Biotechnology
Sector Healthcare
Went public December 1, 2020
Method of going public SPAC
Full time employees 218
Ratings Snapshot
Rating : C
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0